


Olopatadine

Chemical Properties

CAS No. :	113806-05-6
Formula:	C ₂₁ H ₂₃ NO ₃
Molecular Weight:	337.41
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Olopatadine is an orally active, selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits the release of immunostimulatory pro-inflammatory mediators from human conjunctival mast cells and can be used in research on allergic conjunctivitis.
Targets(IC50)	Histamine Receptor
In vitro	Methods: Human conjunctival mast cells and conjunctival epithelial cells were cultured in vitro, treated with olopatadine, and stimulated with anti-IgE antibody. Results: Olopatadine inhibited anti-IgE antibody-mediated release of TNF- α from human conjunctival mast cells and significantly reduced the upregulation of ICAM-1 expression in human conjunctival epithelial cells induced by mast cell supernatants [2].

Solubility Information

Solubility	H ₂ O: Soluble, DMSO: Soluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9638 mL	14.8188 mL	29.6375 mL
5 mM	0.5928 mL	2.9638 mL	5.9275 mL
10 mM	0.2964 mL	1.4819 mL	2.9638 mL
50 mM	0.0593 mL	0.2964 mL	0.5928 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Kam KW, et al. Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. *Ocul Immunol Inflamm.* 2017 Oct;25(5):663-677.
- Yu, W., et al. AMPK-SIRT1 Pathway Modulates The Apoptosis, Proliferation and Migration of AR42J Cells By Regulating p53 and NF- κ B. *European Journal of Pharmacology.* 2021
- Ge S, Wang X, Hou Y, et al. Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2. *European Journal of Pharmacology.* 2021 Apr 5;896:173897. doi: 10.1016/j.ejphar.2021.173897. Epub 2021 Jan 23.
- Leonardi A, et al. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. *Expert Opin Pharmacother.* 2010 Apr;11(6):969-81.
- Roland PS, Ryan MW, Wall GM. Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. *Expert Opin Pharmacother.* 2010 Jun;11(9):1559-67. doi: 10.1517/14656566.2010.485609. Review. PubMed PMID: 20482305.
- Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. *Expert Opin Pharmacother.* 2010 Apr;11(6):969-81. doi: 10.1517/14656561003694643. Review. PubMed PMID: 20307221.
- Ge S, Wang X, Hou Y, et al. Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2[J]. *European Journal of Pharmacology.* 2021: 173897.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481